This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n11	http://dx.doi.org/10.1016/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n5	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q33558073

rdf:type

wikibase:Item

schema:description

2010年论文 научни чланак 2010年論文 ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artículu científicu espublizáu en 2010 vedecký článok 2010年論文 tudományos cikk bilimsel makale 2010年论文 vetenskaplig artikel teaduslik artikkel مقالهٔ علمی 2010 թվականի ապրիլին հրատարակված գիտական հոդված מאמר מדעי 2010年论文 article scientific سائنسی مضمون scientific article article scientifique (publié 2010) мақолаи илмӣ 2010年论文 mokslinis straipsnis 2010年論文 vitenskapelig artikkel artikulong pang-agham wissenschaftlicher Artikel artigo científico (publicado na 2010) artículo científico publicado en 2010 επιστημονικό άρθρο 2010年の論文 article científic мақолаи илмӣ บทความทางวิทยาศาสตร์ 2010年論文 videnskabelig artikel (udgivet 2010) articol științific научная статья vědecký článek 2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած 2010年论文 artykuł naukowy vitskapeleg artikkel 2010年论文 სამეცნიერო სტატია tieteellinen artikkeli 2010年論文 artikull shkencor مقالة علمية scienca artikolo наукова стаття, опублікована у квітні 2010 naučni članak artigo científico (publicado na 2010) 2010 nî lūn-bûn artigo científico научни чланак bài báo khoa học 2010년 논문 wetenschappelijk artikel научна статия articolo scientifico

p:P577

wds:Q33558073-3B21C7EB-E1C7-4E16-9CBC-E947CA52668D

wdt:P577

2010-04-15T00:00:00Z

p:P2093

wds:Q33558073-479AA005-A295-4C97-B338-B9DFF27F900D wds:Q33558073-61AEF8AC-7903-477E-88AC-0FBDAA6CC794 wds:Q33558073-69721C32-FBD2-4628-98CD-8FD2626C298D wds:Q33558073-6AD91566-4C3A-4E99-82DC-D2DD68D72F21 wds:Q33558073-62F7EC20-53EC-49C4-9CD4-BDDCC2322592 wds:Q33558073-83785833-B216-4125-A439-4C265B103303 wds:Q33558073-83469D55-5FD5-402B-9F64-0E360FDB5FDB wds:Q33558073-AFA8516C-474E-42C7-9CD2-43B3C9305920 wds:Q33558073-95FDFE39-8712-49BF-AC20-C61F1EFD370A

wdt:P2093

Leonard Feiner Sarah Gray Amy Chen Rundle BRAVO Investigators Jeffrey S Heier Namrata Saroj Wendy Yee Murahashi Roman G Rubio Peter A Campochiaro

rdfs:label

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

skos:prefLabel

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

schema:name

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

p:P1476

wds:Q33558073-C3CA5237-282B-477B-A458-EDB44669D4BC

wdt:P1476

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

p:P304

wds:Q33558073-8A60C8FF-20A1-48B5-BD99-CC4D122668BB

wdt:P304

1102-1112.e1

p:P31

wds:Q33558073-D4323697-52BA-4E99-A2A1-DD1777F11FCC

wdt:P31

wd:Q13442814

p:P921

wds:Q33558073-AE71DF6C-5E81-4275-9A18-4BC9C7B2B657

wdt:P921

wd:Q18554884

p:P698

wds:Q33558073-E6FE0CF7-AC68-43A2-A997-939D9290C54E

wdtn:P698

n5:20398941

wdt:P698

20398941

p:P1433

wds:Q33558073-62131280-16AC-444B-ADB9-06038AFC9DD4

wdt:P1433

wd:Q7098109

p:P433

wds:Q33558073-3F79F536-0A5E-4B42-BECA-D008659DF339

p:P478

wds:Q33558073-B9C80330-3F55-40AE-B6C1-23F10A658962

wdt:P433

6

wdt:P478

117

p:P356

wds:Q33558073-7849DCE8-A072-4884-99E0-153975635FE5

wdtn:P356

n11:J.OPHTHA.2010.02.021

wdt:P356

10.1016/J.OPHTHA.2010.02.021